Ability of blood cell parameters to predict clinical outcomes of nivolumab monotherapy in advanced esophageal squamous cell carcinoma

Y Hamai, M Emi, Y Ibuki, T Kurokawa… - OncoTargets and …, 2023 - Taylor & Francis
Purpose Various blood cell parameters have been identified as predictive markers of tumor
responses and the survival of patients with cancer treated with immune checkpoint …
被引用次数：5 相关文章
[PDF] scienceopen.com

[PDF][PDF] Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma

Y Hamai, M Emi, Y Ibuki, T Kurokawa… - OncoTargets and …, 2023 - scienceopen.com
Purpose: Various blood cell parameters have been identified as predictive markers of tumor
responses and the survival of patients with cancer treated with immune checkpoint …

[引用][C] Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma

Y Hamai, M Emi, Y Ibuki, T Kurokawa… - OncoTargets and …, 2023 - europepmc.org
Purpose: Various blood cell parameters have been identified as predictive markers of tumor
responses and the survival of patients with cancer treated with immune checkpoint …

Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma

Y Hamai, M Emi, Y Ibuki, T Kurokawa… - OncoTargets and …, 2023 - search.proquest.com
Purpose: Various blood cell parameters have been identified as predictive markers of tumor
responses and the survival of patients with cancer treated with immune checkpoint …

Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma

Y Hamai, M Emi, Y Ibuki, T Kurokawa… - OncoTargets and …, 2023 - dovepress.com
Purpose: Various blood cell parameters have been identified as predictive markers of tumor
responses and the survival of patients with cancer treated with immune checkpoint …

Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma

Y Hamai, M Emi, Y Ibuki, T Kurokawa… - OncoTargets and …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose Various blood cell parameters have been identified as predictive markers of tumor
responses and the survival of patients with cancer treated with immune checkpoint …
[HTML] nih.gov

[HTML][HTML] Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma

Y Hamai, M Emi, Y Ibuki, T Kurokawa… - OncoTargets and …, 2023 - ncbi.nlm.nih.gov
Purpose Various blood cell parameters have been identified as predictive markers of tumor
responses and the survival of patients with cancer treated with immune checkpoint …

Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma.

Y Hamai, M Emi, Y Ibuki, T Kurokawa… - OncoTargets & …, 2023 - search.ebscohost.com
Objective response and disease control rates were 20.3% and 47.5%, respectively. The
LMRs before, and 14 and 28 days after nivolumab initiation were significantly higher in …